New developments in the pathogenesis and treatment of steroid-induced osteoporosis

Journal of Bone and Mineral Research

Volumn 14, Issue 7, 1999, Pages 1061-1066

  Manolagas, Stavros C ^a,b   Weinstein, Robert S ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

APOPTOSIS; BONE REGENERATION; BONE REMODELING; DRUG INDUCED DISEASE; OSTEOBLAST; OSTEOCLAST; OSTEOPOROSIS; PATHOGENESIS; REVIEW;

ANIMALS; APOPTOSIS; BONE DENSITY; BONE REMODELING; GLUCOCORTICOIDS; HUMANS; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; RATS;

EID: 0033007352     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1999.14.7.1061     Document Type: Review

References (38)

1. Cushing H 1932 The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 50:137-195.
2. Reid IR 1998 Glucocorticoid-induced osteoporosis. J Clin Densitometry 1:65-73.
3. Mankin HF 1992 Nontraumatic necrosis of bone (osteonecrosis). N Engl J Med 325:1473-1479.
4. Parfitt AM 1994 Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55:273-286.
5. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311.
6. Abe E, Yamamoto M, Taguchi Y, Lecka-Czernik B, Economides AN, Stahl N, Jilka RL, Manolagas SC 1998 Requirement of BMPs2/4 for postnatal osteoblast and osteoclast formation: Antagonism by noggin. Bone 23:5242 (abstract).
7. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G 1997 Osf2/Cbfal: A transcriptional activator of osteoblast differentiation. Cell 89:747-754.
8. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
9. O'Brien CA, Farrar NC, Manolagas SC 1998 Identification of an OSF-2 binding site in the murine RANKL/OPGL gene promoter: A potential link between osteoblastogenesis and osteoclastogenesis. Bone 23:S149 (abstract).
10. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF 1996 Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat Med 2:1132-1136.
11. Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC 1998 Osteoblast programmed cell death (apoptosis): Modulation by growth factors and cytokines. J Bone Miner Res 13:793-802.
12. Parfitt AM 1990 The osteoblast and osteoclast. Bone 1:351-429.
13. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams D, Abrams J, Broxmeyer H, Manolagas SC1992 Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88-91.
14. Jilka RL, Weinstein RS, Takahashi K, Parfitt AM, Manolagas SC 1996 Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence. J Clin Invest 97:1732-1740.
15. Fitzpatrick LA 1994 Glucocorticoid-induced osteoporosis. In: Marcus R (ed.) Osteoporosis. Blackwell Science, Boston, MA, U.S.A., pp. 202-226.
16. Dempster DW 1989 A prospective: Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 4:137-141.
17. Paz-Pacheo E, Fuleihan GE-H, Leboff MS 1995 Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J Bone Miner Res 10:1713-1718.
18. Pearce G, Tabensky DA, Delmas PD, Baker HWG, Seeman E 1998 Corticosteroid-induced bone loss in men. J Clin Endocrinol Metab 83:801-306.
19. Hahn TJ, Halstead LR, Baran D 1981 Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab 52:111-115.
20. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC 1998 Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteoclasts by glucocorticoids: Potential mechanisms of their deleterious effects on bone. J Clin Invest 102:274-282.
21. Bellido T, Han L, Mocharla H, Said S, O'Brien C, Jilka RL, Manolagas SC 1998 Overexpression of Bcl-2 renders osteoblastic cells refractory to glucocorticoid-induced apoptosis. Bone 23:S324 (abstract).
22. Weinstein RS, Nicholas RW, Kirchner JR, Crawford JA, Skinner RA, Swain FL, Manolagas SC 1998 Anatomic juxtaposition of apoptotic osteoclasts and avascular necrosis in femurs from patients with glucocorticoid-excess. Bone 23:S461 (abstract).
23. Tomkinson A, Reeve J, Shaw RW, Noble BS 1997 The death of osteoclasts via apoptosis accompanies oestrogen withdrawal in human bone. J Clin Endocrinol Metab 82:3128-3135.
24. Frost HM 1960 In vivo osteocyte death. J Bone Joint Surg 42A:138-143.
25. Chang DJ, Ji C, Kim KK, Casinghino S, McCarthy TL, Centrella M 1998 Reduction in transforming growth factor beta receptor I expression and transcription factor Cbfa1 on bone cells by glucocorticoid. J Biol Chem 273:4892-4896.
26. Centrella M, Rosen V, Wozney JM, Casinghino SR, McCarthy TL1997 Opposing effects by glucocorticoid and bone morphogenetic protein-2 in fetal rat bone cell cultures. J Cell Biochem 67:528-540.
27. Canalis E 1998 Inhibitory actions of glucocorticoids on skeleton growth: Is local insulin-like growth factor I to blame? Endocrinology 139:3041-3042.
28. Shi XM, Chang ZJ, Blair HC, McDonald JM, Cao X 1998 Glucocorticoids induce adipogenesis of stromal cells by transcriptionally activating PPARγ2. Bone 23:S454 (abstract).
29. Lecka-Czernik B, Moerman EJ, Lipschitz DA, Manolagas SC, Jilka RL 1999 Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma 2. J Cell Biochem 74:1-14.
30. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387.
31. Reid IR 1997 Preventing glucocorticoid-induced osteoporosis. N Engl J Med 337:420-421.
32. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachus M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292-299.
33. Plotkin LI, Bellido T, Bonewald L, Papapoulos SE, Jilka RL, Manolagas SC 1998 Bisphosphonates prevent glucocorticoid-induced apoptosis of osteocytes in vitro: A putative mechanism influencing mechanosensing. Bone 23:S157 (abstract).
34. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. J Clin Invest 102:1627-1633.
35. Jilka RL, Weinstein RS, Roberson P, Shelton R, Swain F, Smith C, Kirchner J, Parfitt AM, Manolagas SC 1998 PTH increases bone formation by postponing osteoblast apoptosis, not by increasing precursor proliferation. Bone 23:S519 (abstract).
36. Bellido T, Plotkin L, Han L, Manolagas SC, Jilka RL 1998 PTH prevents glucocorticoid-induced apoptosis of osteoblasts and osteoclasts in vitro: Direct interference with a private death pathway upstream from caspase-3. Bone 23:S518 (abstract).
37. Reichardt HM, Kaestner KH, Tuckerman J, Kretz O, Wessely O, Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G 1998 DNA binding of the glucocorticoid receptor is not essential for survival. Cell 93:531-541.
38. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchadeau C, Gronemeyer H, Resche-Rigon M 1997 Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit anti-inflammatory activity in vivo. Mol Endocrinol 11:1245-1255.